United-Guardian Inc
u-g.comUnited-Guardian Inc (NYSE American: UG) is a specialty chemicals manufacturer that produces cosmetic ingredients, personal care and sexual wellness ingredients, medical lubricants, and pharmaceutical products through its Guardian Laboratories division. Revenue is transactional, generated by selling finished specialty chemical and pharmaceutical products to distributors and wholesalers who supply end customers across cosmetic, healthcare, and industrial markets. The company operates from a single manufacturing facility in Hauppauge, New York, with pharmaceutical products representing 51% of total sales in FY2025, up from 39% in FY2024. Key pharmaceutical products include Renacidin, an FDA-approved prescription drug for urethral catheter calcification, and Clorpactin WCS-90, a chlorine-based topical antimicrobial. Cosmetic and personal care ingredients are anchored by the Lubrajel product line, including a COSMOS-certified natural range. A significant share of the company's sales reach international customers, primarily through its largest domestic distributor, ASI, whose foreign sales of UG products were 77% of ASI's total UG product sales in FY2025, with China representing approximately 41% of ASI's sales of those products in FY2025.
Products & Services
Pharmaceutical products: Renacidin (FDA-approved prescription drug for urethral catheter calcification), Clorpactin WCS-90 (chlorine-based topical antimicrobial and disinfectant). Cosmetic and personal care ingredients: Lubrajel line (including Lubrajel Natural, Lubrajel Marine, Lubrajel Oil Natural, Lubrajel Terra, all COSMOS-certified), B-122 powdered lubricant. Medical lubricants distributed in the UK and Ireland through Azelis (agreement signed February 5, 2025). Additional cosmetic ingredients collectively accounted for less than 10% of total sales in FY2025 and FY2024.
Revenue Model
Transactional product sales to distributors and national drug wholesalers. Pharmaceutical products accounted for 51% of total sales in FY2025 and 39% in FY2024. Cosmetic, personal care, and sexual wellness ingredients, along with medical lubricants, comprise the remainder. All sales are denominated in U.S. dollars.
Customers & Markets
Pharmaceutical products sold primarily to three national full-line drug wholesalers supplying pharmacies, physicians, hospitals, and long-term care facilities. Cosmetic and personal care ingredients sold to formulation customers in the cosmetics and personal care industry, including manufacturers prioritizing natural and sustainable inputs. Medical lubricants sold to medical device and healthcare product makers. Receivables are highly concentrated in a small number of customers. ASI is the largest distributor; 77% of ASI's sales of UG products in FY2025 were to foreign customers, with China as ASI's largest foreign market at approximately 41% of ASI's UG product sales in FY2025.
Geographic Exposure
Manufacturing based in Hauppauge, New York. Domestic sales include all shipments to ASI, which are delivered to ASI's U.S. warehouses even though 77% of ASI's UG product sales in FY2025 reached foreign customers. China was ASI's largest foreign market, accounting for approximately 41% of ASI's UG product sales in FY2025. Medical lubricant distribution rights granted to Azelis for the UK and Ireland in February 2025. Raw materials sourced predominantly from U.S.-based suppliers; three suppliers source from China and one direct supplier is located in China.
Loading...
